New Delhi : Corbevax has become the third Covid-19 vaccine for administration in adolescents after India’s drug regulator gave a nod for its emergency use authorisation, Pharmaceutical major Biological E’s announced on Monday.
The Cobrevax has been permitted for use in 12-18 years of the population making it the third Covid jab approved for this age cohort after Zydus Cadila’s ZyCoV-D and Bharat Biotech’s Covaxin. However, only Covaxin has been used in immunization so far among teenagers aged 15-17 years. According to the firm, Corbevax is India’s first indigenously developed Receptor Binding Domain (RBD) Protein sub-unit vaccine against Covid-19.
It received approval for vaccine’s use in adolescents based on interim results (of the ongoing phase II/III clinical study). The vaccine has already received the emergency use authorisation (EUA) among adults on December 28, 2019. Mahima Datla, Managing Director, Biological E Limited, said, “We are pleased with this significant development, which helps extend the reach of our vaccine to the age group of 12 to 18 years in our country.
We truly believe that with this approval, we are even more closer to finishing our global fight against the COVID-19 pandemic.” Corbevax is an intramuscular vaccine with two doses of 0.5 ml each scheduled at 28 days apart. It is stored at 2 to 8 degrees Celsius temperature.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
Related
